Drug Profile
R 348
Alternative Names: R 932348; R348Latest Information Update: 28 Feb 2017
Price :
$50
*
At a glance
- Originator Rigel Pharmaceuticals
- Class Antirheumatics; Eye disorder therapies; Skin disorder therapies; Small molecules
- Mechanism of Action Janus kinase 3 inhibitors; Syk kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Graft-versus-host disease; Keratoconjunctivitis sicca; Psoriasis; Rheumatoid arthritis; Skin disorders; Transplant rejection
Most Recent Events
- 27 Feb 2017 Discontinued - Phase-II for Graft-versus-host disease in USA (Ophthalmic)
- 01 Jul 2016 Rigel Pharmaceuticals completes the phase II DROPS-2 trial for Keratoconjunctivitis sicca in patients with ocular Graft-versus-host disease in USA (NCT02040623)
- 13 Aug 2014 Discontinued - Phase-II for Keratoconjunctivitis sicca in USA (Ophthalmic)